[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559046":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":31,"locations":41,"responsibleParty":75,"collaborators":10,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University Hospital, Rouen","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Multiple myeloma (MM) patient group",null,"patients with multiple myeloma (MM) (defined by a clonal proliferation of tumour plasma cells (\\>10%), the presence of a monoclonal peak in the serum or urine (excluding non-secretory myeloma) and organ damage secondary to bone marrow invasion)",[13],"Biological: Evaluation of the presence and number of mutated alleles of the GBA\u002FPSAP genes in patients with MM or MGUS",{"label":15,"type":10,"description":16,"interventionNames":17},"Monoclonal gammopathy of undetermined significance (MGUS) patient group","patients with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g\u002FL and no clinical involvement)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Control group","patient with no pathology under study relating to the project",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","Evaluation of the presence and number of mutated alleles of the GBA\u002FPSAP genes in patients with MM or MGUS","Estimation of the frequency of variants in the PSAP\u002FGBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.",[19,15,9],[29,30],"Evaluation of plasma concentrations of LGL1 in patients with MM or MGUS compared to controls","Evaluation of the % Reactivity of plasma immunoglobulins from patients with MM or MGUS towards LGL1",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Abdellah AB TEBANI, Pr","CONTACT","02 32 88 81 24","+33","Abdellah.Tebani@chu-rouen.fr",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Soumeya BEKRI, Pr","soumeya.bekri@chu-rouen.fr",[42,60],{"facility":43,"status":44,"city":45,"state":10,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Centre Henri Becquerel","NOT_YET_RECRUITING","Rouen","76000","France","FR",{"type":50,"coordinates":51},"Point",[52,53],1.09932,49.44313,{"lat":53,"lon":52},[56],{"name":57,"role":34,"phone":58,"phoneExt":36,"email":59},"Fabrice FJ JARDIN, Professor","02.32.08.24.65","fabrice.jardin@chb.unicancer.fr",{"facility":61,"status":62,"city":45,"state":10,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"University Rouen Hospital","RECRUITING","76031",{"type":50,"coordinates":65},[52,53],{"lat":53,"lon":52},[68,72],{"name":69,"role":34,"phone":70,"phoneExt":36,"email":71},"Gaétan GS SAUVETRE, Doctor","0232889318","Gaetan.Sauvetre@chu-rouen.fr",{"name":73,"role":34,"phone":70,"phoneExt":36,"email":74},"Hélène HG GOMEZ, Doctor","Helene.Gomez@chu-rouen.fr",{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100559046","determine-the-frequency-of-variants-in-the-gbapsap-genes-in-patients-with-mm-or-mgus-100559046",false,"NCT06559033","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With MM or MGUS","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)","GAMY","Inclusion Criteria:\n\n* Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g\u002FL and no clinical involvement).\n* Membership of a social security scheme\n* Adult having read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub-guardianship or guardianship",true,"ALL","18 Years",{"count":89,"type":90},300,"ESTIMATED","OBSERVATIONAL","No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.",[94,95],"Monoclonal Gammopathy of Undetermined Significance","Myeloma Multiple","2026-06-08",{"date":98,"type":99},"2026-06-10","ACTUAL",{"date":101,"type":99},"2025-10-07",{"date":103,"type":90},"2027-04-01",{"name":5,"class":6},2]